ACSL4 accelerates osteosarcoma progression via modulating TGF-β/Smad2 signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Osteosarcoma (OS) is a primary bone cancer.
• The role of Acyl-CoA synthetase long-chain family member 4 (ACSL4) in OS is not well understood.
• ACSL4 is implicated as an oncogene in various cancers.

Purpose of the Study:

• Investigate ACSL4 expression in OS.
• Determine the biological function of ACSL4 in OS cell proliferation, migration, and apoptosis.
• Elucidate the molecular mechanism by which ACSL4 influences OS progression.

Main Methods:

• Immunohistochemistry (IHC) staining of human tissue microarrays.
• Quantitative real-time PCR (qPCR) assays.
• Loss-of-function experiments using ACSL4-depleted cell lines (MNNG/HOS, U-2OS).
• In vivo studies using a subcutaneous xenograft mice model.
• Western blot analysis to assess protein phosphorylation (Smad2).
• Treatment with TGF-β inhibitor.

Main Results:

• ACSL4 expression is significantly upregulated in OS tissues and cells.
• ACSL4 knockdown suppressed OS cell proliferation, induced G2 phase arrest and apoptosis, and inhibited migration.
• In vivo, ACSL4 silencing impaired tumor growth in xenograft mice.
• ACSL4 regulates Smad2 phosphorylation, and TGF-β inhibition counteracted ACSL4's pro-tumor effects.
• ACSL4 modulates osteosarcoma progression via the TGF-β/Smad2 signaling pathway.

Conclusions:

• ACSL4 is a key driver of osteosarcoma progression.
• Targeting ACSL4 may represent a novel therapeutic strategy for OS.
• ACSL4's role in OS pathogenesis involves the TGF-β/Smad2 signaling pathway.